Home › Urothelial (Transitional Cell) Carcinoma
Urothelial (Transitional Cell) Carcinoma clinical trials recruiting in the U.S.
72 studies for Urothelial (Transitional Cell) Carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
- Orange, CA10 studies
- Philadelphia, PA9 studies
- Washington, DC9 studies
- Columbus, OH9 studies
- Baldwin Park, CA9 studies
- Atlanta, GA8 studies
- Durham, NC8 studies
- Cleveland, OH8 studies
- Jacksonville, FL8 studies
- Seattle, WA8 studies
- Irvine, CA8 studies
- Orlando, FL7 studies
- Portland, OR7 studies
- Omaha, NE7 studies
- San Francisco, CA7 studies
- St. Louis, MO7 studies
- New Rochelle, NY7 studies
- Staten Island, NY7 studies
- Greenburgh, NY7 studies
- Milwaukee, WI6 studies
- Denver, CO6 studies
- Detroit, MI6 studies
- New Haven, CT6 studies
- Gainesville, FL6 studies
- Phoenix, AZ6 studies
- Oklahoma City, OK6 studies
- Charlotte, NC6 studies
- Ann Arbor, MI6 studies
By state
- Alabama4 studies
- Arizona10 studies
- Arkansas5 studies
- California33 studies
- Colorado10 studies
- Connecticut7 studies
- District of Columbia7 studies
- Florida22 studies
- Georgia11 studies
- Idaho4 studies
- Illinois21 studies
- Indiana7 studies
- Iowa7 studies
- Kentucky4 studies
- Louisiana4 studies
- Maryland8 studies
- Massachusetts15 studies
- Michigan15 studies
- Minnesota7 studies
- Missouri10 studies
- Montana3 studies
- Nebraska7 studies
- Nevada3 studies
- New Jersey21 studies
- New York29 studies
- North Carolina15 studies
- Ohio17 studies
- Oklahoma8 studies
- Oregon8 studies
- Pennsylvania15 studies
- South Carolina8 studies
- South Dakota3 studies
- Tennessee25 studies
- Texas38 studies
- Utah6 studies
- Virginia21 studies
- Washington12 studies
- Wisconsin9 studies
Recently updated studies
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06265285Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06524544A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07090499Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
Recruiting
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06262516The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07566156Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921DBC-664 in Adult Patients With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07705035A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05562830Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06439836Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT05239624Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07043972A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07532902GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04977453A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07815665A Study of GEN1106 in Participants With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07416123A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
Recruiting
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06040762Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.